

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1623kxg

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \*    Welcome to STN International    \* \* \* \* \* \* \* \* \*

NEWS 1                Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Apr 08        "Ask CAS" for self-help around the clock  
NEWS 3 Apr 09        BEILSTEIN: Reload and Implementation of a New Subject Area  
NEWS 4 Apr 09        ZDB will be removed from STN  
NEWS 5 Apr 19        US Patent Applications available in IFICDB, IFIPAT, and IFIUDB  
NEWS 6 Apr 22        Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS  
NEWS 7 Apr 22        BIOSIS Gene Names now available in TOXCENTER  
NEWS 8 Apr 22        Federal Research in Progress (FEDRIP) now available  
NEWS 9 Jun 03        New e-mail delivery for search results now available  
NEWS 10 Jun 10       MEDLINE Reload  
NEWS 11 Jun 10       PCTFULL has been reloaded  
NEWS 12 Jul 02       FOREGE no longer contains STANDARDS file segment  
NEWS 13 Jul 22       USAN to be reloaded July 28, 2002;  
                      saved answer sets no longer valid  
NEWS 14 Jul 29       Enhanced polymer searching in REGISTRY  
NEWS 15 Jul 30       NETFIRST to be removed from STN  
NEWS 16 Aug 08       CANCERLIT reload  
NEWS 17 Aug 08       PHARMAMarketLetter(PHARMAML) - new on STN  
NEWS 18 Aug 08       NTIS has been reloaded and enhanced  
NEWS 19 Aug 19       Aquatic Toxicity Information Retrieval (AQUIRE)  
                      now available on STN  
NEWS 20 Aug 19       IFIPAT, IFICDB, and IFIUDB have been reloaded  
NEWS 21 Aug 19       The MEDLINE file segment of TOXCENTER has been reloaded  
NEWS 22 Aug 26       Sequence searching in REGISTRY enhanced  
NEWS 23 Sep 03       JAPIO has been reloaded and enhanced  
NEWS 24 Sep 16       Experimental properties added to the REGISTRY file  
NEWS 25 Sep 16       CA Section Thesaurus available in CAPLUS and CA  
NEWS 26 Oct 01       CASREACT Enriched with Reactions from 1907 to 1985  
NEWS 27 Oct 21       EVENTLINE has been reloaded  
NEWS 28 Oct 24       BEILSTEIN adds new search fields  
NEWS 29 Oct 24       Nutraceuticals International (NUTRACEUT) now available on STN  
NEWS 30 Oct 25       MEDLINE SDI run of October 8, 2002  
NEWS 31 Nov 18       DKILIT has been renamed APOLLIT  
NEWS 32 Nov 25       More calculated properties added to REGISTRY  
NEWS 33 Dec 02       TIBKAT will be removed from STN  
NEWS 34 Dec 04       CSA files on STN  
NEWS 35 Dec 17       PCTFULL now covers WP/PCT Applications from 1978 to date  
NEWS 36 Dec 17       TOXCENTER enhanced with additional content  
NEWS 37 Dec 17       Adis Clinical Trials Insight now available on STN  
NEWS 38 Dec 30       ISMEC no longer available  
NEWS 39 Jan 21       NUTRACEUT offering one free connect hour in February 2003  
NEWS 40 Jan 21       PHARMAML offering one free connect hour in February 2003  
NEWS 41 Jan 29       Simultaneous left and right truncation added to COMPENDEX,  
                      ENERGY, INSPEC  
NEWS 42 Feb 13       CANCERLIT is no longer being updated  
NEWS 43 Feb 24       METADEX enhancements  
NEWS 44 Feb 24       PCTGEN now available on STN  
NEWS 45 Feb 24       TEMA now available on STN

NEWS 46 Feb 26 NTIS now allows simultaneous left and right truncation  
NEWS 47 Feb 26 PCTFULL now contains images  
NEWS 48 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results  
NEWS 49 Mar 19 APOLLIT offering free connect time in April 2003  
NEWS 50 Mar 20 EVENTLINE will be removed from STN  
NEWS 51 Mar 24 PATDPAFULL now available on STN  
NEWS 52 Mar 24 Additional information for trade-named substances without structures available in REGISTRY  
NEWS 53 Mar 24 Indexing from 1957 to 1966 added to records in CA/CAPLUS

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,  
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 10:28:06 ON 01 APR 2003

FILE 'APOLLIT' ENTERED AT 10:28:22 ON 01 APR 2003  
COPYRIGHT (c) 2003 FIZ Karlsruhe

FILE 'BABS' ENTERED AT 10:28:22 ON 01 APR 2003  
COPYRIGHT (c) 2003 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften  
licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

FILE 'CAPLUS' ENTERED AT 10:28:22 ON 01 APR 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 10:28:22 ON 01 APR 2003  
COPYRIGHT (c) 2003 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CEN' ENTERED AT 10:28:22 ON 01 APR 2003  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 10:28:22 ON 01 APR 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'EMA' ENTERED AT 10:28:22 ON 01 APR 2003

COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 10:28:22 ON 01 APR 2003

COPYRIGHT (C) 2003 IFI CLAIMS(R) Patent Services (IFI)

FILE 'JICST-EPLUS' ENTERED AT 10:28:22 ON 01 APR 2003

COPYRIGHT (C) 2003 Japan Science and Technology Corporation (JST)

FILE 'PASCAL' ENTERED AT 10:28:22 ON 01 APR 2003

Any reproduction or dissemination in part or in full,  
by means of any process and on any support whatsoever  
is prohibited without the prior written agreement of INIST-CNRS.  
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

FILE 'PLASNEWS' ENTERED AT 10:28:22 ON 01 APR 2003

Copyright (C) 2003 Bill Communications, Inc. (BCI)

FILE 'PROMT' ENTERED AT 10:28:22 ON 01 APR 2003

COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'RAPRA' ENTERED AT 10:28:22 ON 01 APR 2003

COPYRIGHT (C) 2003 RAPRA Technology Ltd.

FILE 'SCISEARCH' ENTERED AT 10:28:22 ON 01 APR 2003

COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'TEXTILETECH' ENTERED AT 10:28:22 ON 01 APR 2003

COPYRIGHT (C) 2003 Inst. of Textile Technology

FILE 'USPATFULL' ENTERED AT 10:28:22 ON 01 APR 2003

CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 10:28:22 ON 01 APR 2003

CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPIINDEX' ENTERED AT 10:28:22 ON 01 APR 2003

COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WTEXTILES' ENTERED AT 10:28:22 ON 01 APR 2003

COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

=> s composition

16 FILES SEARCHED...

L1 4583415 COMPOSITION

=> s l1 and (polysaccharide and ?amine)

LEFT TRUNCATION IGNORED FOR '?AMINE' FOR FILE 'APOLLIT'

LEFT TRUNCATION IGNORED FOR '?AMINE' FOR FILE 'BABS'

LEFT TRUNCATION IGNORED FOR '?AMINE' FOR FILE 'CBNB'

LEFT TRUNCATION IGNORED FOR '?AMINE' FOR FILE 'CEN'

LEFT TRUNCATION IGNORED FOR '?AMINE' FOR FILE 'EMA'

LEFT TRUNCATION IGNORED FOR '?AMINE' FOR FILE 'IFIPAT'

LEFT TRUNCATION IGNORED FOR '?AMINE' FOR FILE 'JICST-EPLUS'

LEFT TRUNCATION IGNORED FOR '?AMINE' FOR FILE 'PASCAL'

LEFT TRUNCATION IGNORED FOR '?AMINE' FOR FILE 'PLASNEWS'

LEFT TRUNCATION IGNORED FOR '?AMINE' FOR FILE 'PROMT'

LEFT TRUNCATION IGNORED FOR '?AMINE' FOR FILE 'RAPRA'

14 FILES SEARCHED...

LEFT TRUNCATION IGNORED FOR '?AMINE' FOR FILE 'TEXTILETECH'

16 FILES SEARCHED...

18 FILES SEARCHED...

LEFT TRUNCATION IGNORED FOR '?AMINE' FOR FILE 'WTEXTILES'

L2 26461 L1 AND (POLYSACCHARIDE AND ?AMINE)  
Left truncation is not valid in the specified search field in the  
specified file. The term has been searched without left truncation.  
Examples: '?TERPEN?' would be searched as 'TERPEN?' and '?FLAVONOID'  
would be searched as 'FLAVONOID.'

If you are searching in a field that uses implied proximity, and you  
used a truncation symbol after a punctuation mark, the system may  
interpret the truncation symbol as being at the beginning of a term.  
Implied proximity is used in search fields indexed as single words,  
for example, the Basic Index.

```
=> s 11 and (polysaccharide and polyamine)
L3      3258 L1 AND (POLYSACCHARIDE AND POLYAMINE)

=> s 13 and (alkyl or hydrophob? or amphiphil?)
L4      2816 L3 AND (ALKYL OR HYDROPHOB? OR AMPHIPHIL?)

=> s 14 and (nucleic or protein)
  15 FILES SEARCHED...
L5      1815 L4 AND (NUCLEIC OR PROTEIN)

=> s 15 and (dextran or arabinogalactan or pullulan or cellulose or cellobiose or
inulin or chitosan or alginate or hyaluron?)
  16 FILES SEARCHED...
L6      1616 L5 AND (DEXTRAN OR ARABINOGALACTAN OR PULLULAN OR CELLULOSE
OR CELLOBIOSE OR INULIN OR CHITOSAN OR ALGINATE OR HYALURON?)

=> s 16 and (spermine or spermidine or polyethyleneimine)
L7      559 L6 AND (SPERMINE OR SPERMINDE OR POLYETHYLENEIMINE)

=> s 17 and (biological or membrane)
L8      405 L7 AND (BIOLOGICAL OR MEMBRANE)

=> s 18 and biodegra?
L9      255 L8 AND BIODEGRA?

=> s 19 and (cell or transfect?)
  16 FILES SEARCHED...
L10     245 L9 AND (CELL OR TRANSFECT?)

=> s 110 and peptide
L11     220 L10 AND PEPTIDE

=> s 111 and (polynucleic or oligonucleotide or antisense)
L12     204 L11 AND (POLYNUCLEIC OR OLIGONUCLEOTIDE OR ANTISENSE)

=> s 112 and (fatty or oleic or glycol)
L13     203 L12 AND (FATTY OR OLEIC OR GLYCOL)

=> s 114 and (toxic or immunog?)
L14 NOT FOUND
The L-number entered could not be found. To see the definition
of L-numbers, enter DISPLAY HISTORY at an arrow prompt (>).

=> s 113 and (toxic or immunog?)
L14     40 L13 AND (TOXIC OR IMMUNOG?)

=> dis 114 1-40 bib abs
COMMAND INTERRUPTED
```

If this message appears repeatedly, please notify the Help Desk.  
Enter "HELP STN" for information on contacting the nearest STN Help  
Desk by telephone or via SEND in the STNMAIL file.

```
=> index polymers
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                                ENTRY        SESSION
FULL ESTIMATED COST          162.56       162.77

INDEX 'APOLLIT, BABS, CAPLUS, CBNB, CEN, CIN, EMA, IFIPAT, JICST-EPLUS, PASCAL,
PLASNEWS, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL, USPAT2, WPIDS,
WPIINDEX, WTEXTILES' ENTERED AT 10:43:00 ON 01 APR 2003
```

20 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view  
search error messages that display as 0\* with SET DETAIL OFF.

=> dis hist

(FILE 'HOME' ENTERED AT 10:28:06 ON 01 APR 2003)

FILE 'APOLLIT, BABS, CAPLUS, CBNB, CEN, CIN, EMA, IFIPAT, JICST-EPLUS,
PASCAL, PLASNEWS, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL,
USPAT2, WPIINDEX, WTEXTILES' ENTERED AT 10:28:22 ON 01 APR 2003

L1	4583415 S COMPOSITION
L2	26461 S L1 AND (POLYSACCHARIDE AND ?AMINE)
L3	3258 S L1 AND (POLYSACCHARIDE AND POLYAMINE)
L4	2816 S L3 AND (ALKYL OR HYDROPHOB? OR AMPHIPHIL?)
L5	1815 S L4 AND (NUCLEIC OR PROTEIN)
L6	1616 S L5 AND (DEXTRAN OR ARABINOGALACTAN OR PULLULAN OR CELLULOSE)
L7	559 S L6 AND (SPERMINE OR SPERMIDINE OR POLYETHYLENEIMINE)
L8	405 S L7 AND (BIOLOGICAL OR MEMBRANE)
L9	255 S L8 AND BIODEGRA?
L10	245 S L9 AND (CELL OR TRANSFECT?)
L11	220 S L10 AND PEPTIDE
L12	204 S L11 AND (POLYNUCLEIC OR OLIGONUCLEOTIDE OR ANTISENSE)
L13	203 S L12 AND (FATTY OR OLEIC OR GLYCOL)
L14	40 S L13 AND (TOXIC OR IMMUNOG?)

INDEX 'APOLLIT, BABS, CAPLUS, CBNB, CEN, CIN, EMA, IFIPAT, JICST-EPLUS,
PASCAL, PLASNEWS, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL,
USPAT2, WPIDS, WPIINDEX, WTEXTILES' ENTERED AT 10:43:00 ON 01 APR 2003

=> s l14
9 FILES SEARCHED...
14 FILES SEARCHED...
 40 FILE USPATFULL
18 FILES SEARCHED...

1 FILES HAVE ONE OR MORE ANSWERS, 20 FILES SEARCHED IN STNINDEX

L15 QUE L14

=> d rank
F1 40 USPATFULL

COST IN U.S. DOLLARS          SINCE FILE      TOTAL	
	ENTRY        SESSION
FULL ESTIMATED COST          2.75         165.52	

FILE 'USPATFULL' ENTERED AT 10:45:45 ON 01 APR 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 1 Apr 2003 (20030401/PD)

FILE LAST UPDATED: 1 Apr 2003 (20030401/ED)  
HIGHEST GRANTED PATENT NUMBER: US6543053  
HIGHEST APPLICATION PUBLICATION NUMBER: US2003061649  
CA INDEXING IS CURRENT THROUGH 1 Apr 2003 (20030401/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 1 Apr 2003 (20030401/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2003  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2003

>>> USPAT2 is now available. USPATFULL contains full text of the <<<  
>>> original, i.e., the earliest published granted patents or <<<  
>>> applications. USPAT2 contains full text of the latest US <<<  
>>> publications, starting in 2001, for the inventions covered in <<<  
>>> USPATFULL. A USPATFULL record contains not only the original <<<  
>>> published document but also a list of any subsequent <<<  
>>> publications. The publication number, patent kind code, and <<<  
>>> publication date for all the US publications for an invention <<<  
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<  
>>> records and may be searched in standard search fields, e.g., /PN, <<<  
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<  
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<  
>>> enter this cluster. <<<  
>>> <<<  
>>> Use USPATALL when searching terms such as patent assignees, <<<  
>>> classifications, or claims, that may potentially change from <<<  
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l14
    130658 TOXIC
    273 TOXICS
    130738 TOXIC
        (TOXIC OR TOXICS)
    39419 IMMUNOG?
L16      40 L13 AND (TOXIC OR IMMUNOG?)
```

```
=> dis l16 1-40 bib abs
```

```
L16 ANSWER 1 OF 40 USPATFULL
AN 2003:78450 USPATFULL
TI Systematic discovery of new genes and genes discovered thereby
IN Zeng, Qiandong, Belmont, MA, UNITED STATES
Kessler, Marco M., Peabody, MA, UNITED STATES
Cottarel, Guillaume, Arlington, MA, UNITED STATES
PI US 2003054370 A1 20030320
AI US 2002-83357 A1 20020227 (10)
PRAI US 2001-271406P 20010227 (60)
        US 2001-333726P 20011129 (60)
DT Utility
FS APPLICATION
LREP BURNS DOANE SWECKER & MATHIS L L P, POST OFFICE BOX 1404, ALEXANDRIA,
VA, 22313-1404
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 5941
AB The present invention is directed to a systematic in silico method to
identify new coding sequences, including homologs of coding sequences,
in S. cerevisiae and other organisms. The present invention is also
directed to novel ORFs and the proteins encoded thereby
identified using the in silico methods.
```

L16 ANSWER 2 OF 40 USPATFULL  
AN 2003:71358 USPATFULL  
TI Constitutively desensitized G protein-coupled receptors  
IN Barak, Larry S., Durham, NC, UNITED STATES  
Oakley, Robert H., Durham, NC, UNITED STATES  
Caron, Marc G., Durham, NC, UNITED STATES  
Laporte, Stephane A., Outremont, CANADA  
Wilbanks, Alyson, Chapel Hill, NC, UNITED STATES  
PI US 2003049643 A1 20030313  
AI US 2002-54616 A1 20020122 (10)  
PRAI US 2001-263406P 20010123 (60)  
DT Utility  
FS APPLICATION  
LREP BURNS DOANE SWECKER & MATHIS L L P, POST OFFICE BOX 1404, ALEXANDRIA,  
VA, 22313-1404  
CLMN Number of Claims: 55  
ECL Exemplary Claim: 1  
DRWN 27 Drawing Page(s)  
LN.CNT 4934

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to modified G-protein coupled receptors (GPCRs). The modified GPCRs of the present invention include GPCRs that have been modified to have altered DRY motifs such that the modified GPCRs are constitutively desensitized. As such, the modified GPCRs of the present invention preferably localize to endocytic vesicles or endosomes in an agonist-independent manner. The invention also relates to methods of screening compounds and sample solutions for GPCR activity using the modified GPCRs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 3 OF 40 USPATFULL  
AN 2003:70968 USPATFULL  
TI Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines  
IN Li, Frank Q., Montgomery Village, MD, UNITED STATES  
Chu, Yong-Liang, Rockville, MD, UNITED STATES  
Qiu, Jian-Tai, Rockville, MD, UNITED STATES  
PI US 2003049253 A1 20030313  
AI US 2002-62710 A1 20020205 (10)  
PRAI US 2001-310498P 20010808 (60)  
DT Utility  
FS APPLICATION  
LREP Supervisor, Patent Prosecution Services, PIPER MARBURY RUDNICK & WOLFE  
LLP, 1200 Nineteenth Street, N.W., Washington, DC, 20036-2412  
CLMN Number of Claims: 14  
ECL Exemplary Claim: 1  
DRWN 5 Drawing Page(s)  
LN.CNT 1790

AB A method and compositions for modulating an immune system response to an antigen in a mammal are disclosed. The method comprises administering to the mammal a conjugate comprising substantially particle-free hyaluronic acid (HA), or a polymer analogue thereof, covalently linked to a peptide that comprises a T cell epitope, or a plurality of epitopes. Typically, the epitope is defined by a sequence of at least about eight amino acids of the antigen.

L16 ANSWER 4 OF 40 USPATFULL  
AN 2003:57931 USPATFULL  
TI Compositions and methods for non-parenteral delivery of

IN           **oligonucleotides**  
Teng, Ching-Leou, San Diego, CA, UNITED STATES  
Cook, Phillip Dan, Fallbrook, CA, UNITED STATES  
Tillman, Lloyd, Carlsbad, CA, UNITED STATES  
Hardee, Gregory E., Rancho Sante Fe, CA, UNITED STATES  
Ecker, David J., Encinitas, CA, UNITED STATES  
Manoharan, Muthiah, Carlsbad, CA, UNITED STATES  
PI           US 2003040497       A1    20030227  
AI           US 2001-29598      A1    20011221 (10)  
RLI          Continuation of Ser. No. US 1999-315298, filed on 20 May 1999, PENDING  
Continuation of Ser. No. US 1998-108673, filed on 1 Jul 1998, PENDING  
Continuation-in-part of Ser. No. US 1997-886829, filed on 1 Jul 1997,  
ABANDONED  
DT           Utility  
FS           APPLICATION  
LREP        Michael P. Straher, Woodcock Washburn LLP, One Liberty Place-46th Floor,  
Philadelphia, PA, 19103  
CLMN        Number of Claims: 26  
ECL          Exemplary Claim: 1  
DRWN        No Drawings  
LN.CNT      3600

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB          The present invention relates to **compositions** and methods which enhance the local and systemic uptake and delivery of **oligonucleotides** and **nucleic acids** via non-parenteral routes of administration. Pharmaceutical **compositions** comprising **oligonucleotides** disclosed herein include, for systemic delivery, emulsion and microemulsion formulations for a variety of applications and oral dosage formulations. It has also surprisingly been discovered that **oligonucleotides** may be locally delivered to colonic sites by rectal enemas and suppositories in simple solutions, e.g., neat or in saline. Such pharmaceutical **compositions** of **oligonucleotides** may further include one or more penetration enhancers for the transport of **oligonucleotides** and other **nucleic acids** across mucosal **membranes**. The **compositions** and methods of the invention are utilized to effect the oral, buccal, rectal or vaginal administration of an **antisense oligonucleotide** to an animal in order to modulate the expression of a gene in the animal for investigative, therapeutic, palliative or prophylactic purposes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16        ANSWER 5 OF 40    USPATFULL  
AN        2003:39271    USPATFULL  
TI        Antimicrobial polypeptides and their uses  
IN        Altier, Daniel J., Waukee, IA, UNITED STATES  
          Herrmann, Rafael, Wilmington, DE, UNITED STATES  
          Lu, Albert L., Newark, DE, UNITED STATES  
          McCutchen, Billy F., Clive, IA, UNITED STATES  
          Presnail, James K., Avondale, PA, UNITED STATES  
          Weaver, Janine L., Bear, DE, UNITED STATES  
          Wong, James F.H., Johnston, IA, UNITED STATES  
PA        Pioneer Hi-Bred International, Inc. (U.S. corporation)  
PI        US 2003028920      A1    20030206  
AI        US 2002-125258      A1    20020418 (10)  
PRAI      US 2001-285355P     20010420 (60)  
DT        Utility  
FS        APPLICATION  
LREP      ALSTON & BIRD LLP, PIONEER HI-BRED INTERNATIONAL, INC., BANK OF AMERICA  
          PLAZA, 101 SOUTH TYRON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000  
CLMN      Number of Claims: 23  
ECL        Exemplary Claim: 1  
DRWN      3 Drawing Page(s)

LN.CNT 5402

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The methods and **compositions** of the present invention find use in impacting microbial pathogens and in enhancing disease resistance to pathogens, particularly by plants. The **compositions** of the invention include polypeptides that possess antimicrobial properties, particularly fungicidal properties, and the encoding nucleic acid molecules. The polypeptides of the invention are isolated from the hemolymph and fat bodies of insect larvae induced by injection of plant pathogenic fungi. Further provided are plant **cells**, plants, and seed thereof, transformed with the nucleic acid molecules of the invention so as to confer disease resistance on the plant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 6 OF 40 USPATFULL

AN 2002:273397 USPATFULL

TI Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation

IN Collins, Douglas A., Rochester, MN, UNITED STATES

Hogenkamp, Henricus P.C., Roseville, MN, UNITED STATES

PI US 2002151525 A1 20021017

AI US 2001-27593 A1 20011025 (10)

PRAI US 2000-243082P 20001025 (60)

US 2000-243112P 20001025 (60)

DT Utility

FS APPLICATION

LREP KING & SPALDING, 191 PEACHTREE STREET, N.E., ATLANTA, GA, 30303-1763

CLMN Number of Claims: 28

ECL Exemplary Claim: 1

DRWN 6 Drawing Page(s)

LN.CNT 4143

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An agent, **composition** and method for the treatment, prophylaxis and/or diagnosis of proliferative disorders, which is highly and efficiently absorbed at the site of abnormal cellular proliferation is disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 7 OF 40 USPATFULL

AN 2002:265950 USPATFULL

TI Cationic polysaccharide compositions

*Instant.*

IN Domb, Abraham J., Efrat, ISRAEL

PA Polygene Ltd. (non-U.S. corporation)

PI US 2002146826 A1 20021010

AI US 2002-44538 A1 20020110 (10)

PRAI IL 2001-140844 20010110

DT Utility

FS APPLICATION

LREP PATREA L. PABST, HOLLAND & KNIGHT LLP, SUITE 2000, ONE ATLANTIC CENTER, 1201 WEST PEACHTREE STREET, N.E., ATLANTA, GA, 30309-3400

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1942

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a polycation **composition** comprising a polysaccharide chain having an amount of saccharide units ranging from 2 to 2000, at least one oligoamine directly grafted to said polysaccharide chain per each segment of 5 saccharide units, wherein said oligoamine is selected from the group consisting of a linear, branched and cyclic alkyl amine having at least two amino groups, and at least one further grafted group selected from the

group consisting of a hydrophobic and an amphiphilic group directly grafted to said polysaccharide chain per each segment of 50 saccharide units, wherein said hydrophobic or amphiphilic group includes an aliphatic chain of at least 4 carbons atoms.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 8 OF 40 USPATFULL  
AN 2002:262078 USPATFULL  
TI Tumor delivery vehicles  
IN Fick, James R., Martinez, GA, United States  
PA FBP Corporation, San Francisco, CA, United States (U.S. corporation)  
PI US 6461641 B1 20021008  
AI US 1999-243756 19990203 (9)  
RLI Continuation of Ser. No. US 1996-690535, filed on 31 Jul 1996, now patented, Pat. No. US 5945100  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Nguyen, Dave T.  
LREP Holland & Knight LLP  
CLMN Number of Claims: 16  
ECL Exemplary Claim: 1  
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
LN.CNT 1033

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The major problem with current direct delivery techniques of therapeutic reagents into solid tumors, especially of cells or large volumes of recombinant DNA reagents or drugs, has been resistance of the tissues to the influx of the fluid and/or cells, resulting in low quantities of the fluid and/or cells penetrating into and remaining in the tumor tissue to be treated. Increased penetration and/or reduced backflow and diversion through the point of entry, so that more material is introduced into and remains in the tumor, is obtained through the use of a viscous vehicle, most preferably having a similar density to tissue, for the material to be delivered. Preferred materials include solutions or suspensions of a polymeric material which gel or solidify at the time of or shortly after injection or implantation. In the preferred embodiment, the solution is injected via a catheter into regions of the tumor to be treated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 9 OF 40 USPATFULL  
AN 2002:236036 USPATFULL  
TI Multifunctional polymeric surface coatings in analytic and sensor devices  
IN Hubbell, Jeffrey A., Zumikon, SWITZERLAND  
Textor, Marcus, Schaffhausen, SWITZERLAND  
Elbert, Donald L., Zurich, SWITZERLAND  
Finken, Stephanie, Zurich, SWITZERLAND  
Hofer, Rolf, Biel, SWITZERLAND  
Spencer, Nicholas D., Zollikon, SWITZERLAND  
Ruiz-Taylor, Laurence, Belmont, CA, UNITED STATES  
PI US 2002128234 A1 20020912  
AI US 2000-560472 A1 20000428 (9)  
PRAI US 1999-131391P 19990428 (60)  
US 1999-131402P 19990428 (60)  
US 2000-184616P 20000224 (60)  
DT Utility  
FS APPLICATION  
LREP Patrea L Pabst, Holland & Knight LLP, Suite 2000 One Atlantic Center, 1201 West Peachtree Street N E, Atlanta, GA, 30309-3400  
CLMN Number of Claims: 57

ECL Exemplary Claim: 1  
DRWN 13 Drawing Page(s)  
LN.CNT 2837

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Multifunctional, polyionic copolymers with molecular architectures and properties optimized for specific applications are synthesized on/or applied to substrate surfaces for analytical and sensing purposes. The coatings are particularly useful for suppression of non-specific interaction, adsorption or attachment of molecular or ionic components present in an analyte solution. Chemical, biochemical or biological groups can be coupled to, integrated into or absorbed to the multifunctional polymer that are able to recognize, interact with and bind specifically to target molecules in the material containing the analyte to be detected. These multifunctional polymer coatings are compatible with a variety of different established methods to detect, sense and quantify the target molecule in an analyte. These materials can also be used to modulate biological interactions upon substrate surfaces for use as selective implant surfaces that resist cell attachment and may optionally promote the attachment of specific cell types or induce a particular cellular behavior. The multifunctional polymer coatings typically include brush copolymers based on a polycationic or polyanionic (jointly referred to herein as 'polyionic') backbone with side chains that control interaction with the environment, such as poly(ethylene glycol) or poly(ethylene oxide)-based side chains that decrease cellular adhesion, and analyte-specific side chains. Non-modified and modified copolymers can be used singly, consecutively or as a mixture. They can be used to pattern the surfaces into non-adhesive and specifically adhesive areas by applications of known techniques such as microfluidic or contact printing techniques.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 10 OF 40 USPATFULL  
AN 2002:217220 USPATFULL  
TI Enzymatic cleaning compositions  
IN Bettiol, Jean-Luc Philippe, Brussels, BELGIUM  
Joos, Conny Erna-Alice, Buggenhout, BELGIUM  
PA Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)  
PI US 6440911 B1 20020827  
WO 9909126 19990225  
AI US 2000-485649 20000317 (9)  
WO 1998-US11993 19980610  
20000317 PCT 371 date  
PRAI EP 1997-870120 19970814  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Delcotto, Gregory  
LREP Cook, C. Brant, Zerby, K. W., Miller, Steve W.  
CLMN Number of Claims: 14  
ECL Exemplary Claim: 1  
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
LN.CNT 3753

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to cleaning compositions a mannanase and a carbohydrase selected from cellulases, amylases, pectin degrading enzymes and/or xyloglucanases. These compositions provide superior cleaning performance, i.e. superior stain removal, dingy cleaning and whiteness maintenance.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 11 OF 40 USPATFULL

AN 2002:191539 USPATFULL  
TI Full-length human cDNAs encoding potentially secreted proteins  
IN Milne Edwards, Jean-Baptiste Dumas, Paris, FRANCE  
Bougueret, Lydie, Petit Lancy, SWITZERLAND  
Jobert, Severin, Paris, FRANCE  
PI US 2002102604 A1 20020801  
AI US 2000-731872 A1 20001207 (9)  
PRAI US 1999-169629P 19991208 (60)  
US 2000-187470P 20000306 (60)  
DT Utility  
FS APPLICATION  
LREP John Lucas, Ph.D., J.D., Genset Corporation, 10665 Sorrento Valley Road,  
San Diego, CA, 92121-1609  
CLMN Number of Claims: 29  
ECL Exemplary Claim: 1  
DRWN 5 Drawing Page(s)  
LN.CNT 28061

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 12 OF 40 USPATFULL  
AN 2002:175117 USPATFULL  
TI Detergent compositions comprising a mannanase and a bleach system  
IN Bettiol, Jean-Luc Philippe, Brussels, BELGIUM  
Showell, Michael Stanford, Cincinnati, OH, United States  
Baeck, Andre Cesar, Bonheiden, BELGIUM  
Thoen, Christiaan Arthur Jacques Kamiel, West Chester, OH, United States  
PA Procter & Gamble Company, Cincinnati, OH, United States (U.S.  
corporation)  
PI US 6420331 B1 20020716  
AI US 2000-503565 20000214 (9)  
RLI Continuation-in-part of Ser. No. WO 1998-US12023, filed on 10 Jun 1998,  
now abandoned Continuation-in-part of Ser. No. WO 1998-US12024, filed on  
10 Jun 1998, now abandoned  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Gupta, Yogendra N.; Assistant Examiner: Elhilo, Eisa  
LREP Cook, C. Brant, Zerby, K. W., Miller, Steve W.  
CLMN Number of Claims: 17  
ECL Exemplary Claim: 1  
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
LN.CNT 3669

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to detergent compositions comprising a mannanase enzyme and a bleach system preferably comprising a source of hydrogen peroxide and optionally, but preferably, a hydrophobic bleach activator for superior cleaning, stain removal and/or whiteness performance.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 13 OF 40 USPATFULL  
AN 2002:157632 USPATFULL  
TI Cationic polymers and lipids for the delivery of nucleic acids  
IN Sullivan, Sean M., The Woodlands, TX, UNITED STATES

Meng, Xiao-Ying, Mountain View, CA, UNITED STATES  
PI US 2002082237 A1 20020627  
AI US 2002-84159 A1 20020228 (10)  
RLI Continuation of Ser. No. US 1997-865375, filed on 29 May 1997, ABANDONED  
PRAI US 1996-18377P 19960529 (60)  
DT Utility  
FS APPLICATION  
LREP ROYLANC, ABRAMS, BERDO & GOODMAN, L.L.P., 1300 19TH STREET, N.W., SUITE  
600, WASHINGTON,, DC, 20036  
CLMN Number of Claims: 15  
ECL Exemplary Claim: 1  
DRWN 5 Drawing Page(s)  
LN.CNT 1266

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel cationic polymers and cationic lipids, and methods of making and using the same, are provided. The cationic polymers and cationic lipids are useful for the delivery of nucleic acid polymers and oligomers to cells in vitro and in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 14 OF 40 USPATFULL  
AN 2002:106270 USPATFULL  
TI Antisense modulation of PTP1B expression  
IN Cowser, Lex M., San Mateo, CA, UNITED STATES  
Wyatt, Jacqueline, Encinitas, CA, UNITED STATES  
Freier, Susan M., San Diego, CA, UNITED STATES  
Monia, Brett P., La Costa, CA, UNITED STATES  
Butler, Madeline M., Rancho Santa Fe, CA, UNITED STATES  
McKay, Robert, San Diego, CA, UNITED STATES  
PI US 2002055479 A1 20020509  
AI US 2001-854883 A1 20010514 (9)  
RLI Continuation-in-part of Ser. No. US 2000-629644, filed on 31 Jul 2000,  
PENDING Continuation-in-part of Ser. No. US 2000-487368, filed on 18 Jan  
2000, GRANTED, Pat. No. US 6261840  
DT Utility  
FS APPLICATION  
LREP HOWSON AND HOWSON, Spring House Corporate, Box 457, Spring House, PA,  
19477  
CLMN Number of Claims: 44  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 6714

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 15 OF 40 USPATFULL  
AN 2002:92631 USPATFULL  
TI Cobalamin compounds useful as cardiovascular agents and as imaging agents  
IN Hogenkamp, Henricus P.C., Roseville, MN, UNITED STATES  
PI US 2002049155 A1 20020425  
AI US 2001-873142 A1 20010531 (9)  
PRAI US 2000-208140P 20000531 (60)  
US 2001-267782P 20010209 (60)  
DT Utility

FS APPLICATION  
LREP KING & SPALDING, 191 PEACHTREE STREET, N.E., ATLANTA, GA, 30303-1763  
CLMN Number of Claims: 50  
ECL Exemplary Claim: 1  
DRWN 2 Drawing Page(s)  
LN.CNT 4521

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides cobalamin derivatives linked to a cardiovascular agent, as well as pharmaceutical **compositions** comprising the compounds and methods for using the compounds in treatment or diagnosis of a cardiovascular disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 16 OF 40 USPATFULL  
AN 2002:88439 USPATFULL  
TI Detergent **compositions** comprising a mannanase and a protease  
IN Bettioli, Jean-Luc Philippe, Brussels, BELGIUM  
Showell, Michael Stanford, Cincinnati, OH, United States  
PA Procter & Gamble Company, Cincinnati, OH, United States (U.S.  
corporation)  
PI US 6376445 B1 20020423  
WO 9909128 19990225  
AI US 2000-485648 20000405 (9)  
WO 1998-US11996 19980610  
20000405 PCT 371 date  
PRAI EP 1997-870120 19970814  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Delcotto, Gregory  
LREP Taffy, Frank, Zerby, K. W., Miller, Steve W.  
CLMN Number of Claims: 8  
ECL Exemplary Claim: 1  
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
LN.CNT 3501

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Detergent **compositions** for cleansing fabrics, dishware and hard surfaces contain a mannanase enzyme, a protease enzyme and deteritive ingredients. Mannanase enzymes from *Bacillus agaradherens* and *Bacillus subtilis* strain 168, gene yght, as well as isolated polypeptides therefrom, are used to remove stains.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 17 OF 40 USPATFULL  
AN 2002:78737 USPATFULL  
TI Cobalamin compounds useful as antibiotic agents and as imaging agents  
IN Hogenkamp, Henricus P.C., Roseville, MN, UNITED STATES  
Collins, Douglas A., Rochester, MN, UNITED STATES  
PI US 2002042394 A1 20020411  
AI US 2001-873164 A1 20010531 (9)  
PRAI US 2000-208148P 20000531 (60)  
US 2001-267543P 20010209 (60)  
DT Utility  
FS APPLICATION  
LREP KING & SPALDING, 191 PEACHTREE STREET, N.E., ATLANTA, GA, 30303-1763  
CLMN Number of Claims: 50  
ECL Exemplary Claim: 1  
DRWN 2 Drawing Page(s)  
LN.CNT 4896

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides cobalamin derivatives linked to an antibiotic and/or an imaging agent, as well as pharmaceutical **compositions** comprising the compounds and methods for using the compounds in

treatment or diagnosis of a microbial infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 18 OF 40 USPATFULL  
AN 2002:37547 USPATFULL  
TI Delivery vehicles comprising stable lipid/nucleic acid complexes  
IN Sullivan, Sean M., Danville, CA, UNITED STATES  
Hofland, Hans, San Francisco, CA, UNITED STATES  
PI US 2002022264 A1 20020221  
AI US 2001-809292 A1 20010316 (9)  
RLI Continuation of Ser. No. US 1996-652018, filed on 21 May 1996, ABANDONED  
Continuation-in-part of Ser. No. US 1995-450142, filed on 26 May 1995,  
ABANDONED  
DT Utility  
FS APPLICATION  
LREP ROYLANCE, ABRAMS, BERRO & GOODMAN, L.L.P., 1300 19TH STREET, N.W., SUITE  
600, WASHINGTON,, DC, 20036  
CLMN Number of Claims: 28  
ECL Exemplary Claim: 1  
DRWN 19 Drawing Page(s)  
LN.CNT 1766  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Stable polynucleotide delivery vehicles (SPDVs) are described which incorporate a polynucleotide/cationic lipid complex as structural components of the SPDV. The subject SPDVs may optionally incorporate synthetic **biodegradable** amphipathic lipids, and suitable targeting agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 19 OF 40 USPATFULL  
AN 2002:22163 USPATFULL  
TI Cationic liposomes  
IN Gonda, Igor, San Francisco, CA, UNITED STATES  
Margalit, Rimona, Tel Aviv, ISRAEL  
PI US 2002012998 A1 20020131  
AI US 2001-823256 A1 20010329 (9)  
PRAI US 2000-193062P 20000329 (60)  
DT Utility  
FS APPLICATION  
LREP Paula Borden, BOZICEVIC, FIELD & FRANCIS LLP, 200 Middlefield Road,  
Suite 200, Menlo Park, CA, 94025  
CLMN Number of Claims: 20  
ECL Exemplary Claim: 1  
DRWN 1 Drawing Page(s)  
LN.CNT 1148  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The cationic liposomal formulations of the present invention provide nucleic acid and gene product delivery devices having a glycosaminoglycan covalently attached to the liposome surface. The glycosaminoglycan can be any glycosaminoglycan, including but not limited to **hyaluronic** acid, the chondroitin sulfates, keratan sulfate, chitin and heparin. Preferably, the glycosaminoglycan is **hyaluronic** acid. The present invention also provides methods of preparing the nucleic acid-liposome formulations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 20 OF 40 USPATFULL  
AN 2001:235126 USPATFULL  
TI Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof

IN Levy, Robert J., Merion Station, PA, United States  
Crombleholme, Timothy, Haverford, PA, United States  
Vyawahare, Narendra, Erial, NJ, United States  
PA The Children's Hospital of Philadelphia, Philadelphia, PA, United States  
(U.S. corporation)  
PI US 6333194 B1 20011225  
AI US 2000-487854 20000119 (9)  
PRAI US 1999-116538P 19990119 (60)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: Wang, Andrew; Assistant Examiner: Zara, Jane  
LREP Foley & Lardner  
CLMN Number of Claims: 34  
ECL Exemplary Claim: 1  
DRWN 9 Drawing Figure(s); 3 Drawing Page(s)  
LN.CNT 3154

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to **compositions** and methods for delivering a virus vector to an animal. The **compositions** include **compositions** which comprise a hydrogel matrix (e.g. a collagen matrix which can comprise a poloxamer or an alginate) containing a virus vector therein in a **transfictious** form. The invention also includes methods of making such hydrogel precursor mixtures and hydrogel matrices, including particles, devices, bulk materials, and other objects which comprise, consist of, or are coated with such mixtures or matrices. The invention further relates to **compositions** comprising a hydrogel precursor mixture having a virus vector suspended therein, which, when administered to an animal, gel to form a hydrogel matrix containing a virus vector therein in a **transfictious** form. Methods of delivering a virus vector to an animal tissue are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 21 OF 40 USPATFULL  
AN 2001:212417 USPATFULL  
TI In situ bioreactors and methods of use thereof  
IN Pierce, Glenn, Rancho Santa Fe, CA, United States  
Chandler, Lois Ann, Encinitas, CA, United States  
PI US 2001044413 A1 20011122  
AI US 2000-729644 A1 20001130 (9)  
PRAI US 1999-168470P 19991201 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,  
SEATTLE, WA, 98104-7092  
CLMN Number of Claims: 104  
ECL Exemplary Claim: 1  
DRWN 3 Drawing Page(s)  
LN.CNT 2302

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides in situ bioreactors comprising a biocompatible substance comprising **nucleic** acid molecules and capable of cellular ingrowth and systemic delivery of a bioactive agent. Also provided are **compositions**, devices, and kits comprising the same. In various embodiments the biocompatible substance comprises a matrix and at least one **nucleic** acid molecule encoding a bioactive agent. In other embodiments bioreactors are provided wherein a first gene that encodes a growth factor is present and a second gene encoding a bioactive agent is present during manufacture or provided to the bioreactor following manufacture or implantation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 22 OF 40 USPATFULL  
AN 2001:212416 USPATFULL  
TI Compositions and methods for drug delivery using  
amphiphile binding molecules  
IN Wolff, Jon A., Madison, WI, United States  
Hagstrom, James E., Madison, WI, United States  
Monahan, Sean D., Madison, WI, United States  
Budker, Vladimir, Middleton, WI, United States  
Rozema, David B., Madison, WI, United States  
Slatum, Paul M., Madison, WI, United States  
PI US 2001044412 A1 20011122  
AI US 2000-726792 A1 20001129 (9)  
RLI Continuation-in-part of Ser. No. US 1999-234606, filed on 21 Jan 1999,  
PENDING  
PRAI US 1999-167836P 19991129 (60)  
DT Utility  
FS APPLICATION  
LREP Mark K. Johnson, PO Box 510644, New Berlin, WI, 53151-0644  
CLMN Number of Claims: 20  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2085  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The present invention relates to the delivery of desired compounds  
(e.g., nucleic acids) into cells using noncovalent  
delivery systems which include complexing nucleic acids,  
amphipathic binding agents, and amphiphiles.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 23 OF 40 USPATFULL  
AN 2001:212153 USPATFULL  
TI Delivery vehicles comprising stable lipid/nucleic acid  
complexes  
IN Sullivan, Sean M., Danville, CA, United States  
Hofland, Hans, San Francisco, CA, United States  
PI US 2001044147 A1 20011122  
AI US 2001-855796 A1 20010516 (9)  
RLI Continuation of Ser. No. US 1996-652018, filed on 21 May 1996, PENDING  
Continuation-in-part of Ser. No. US 1995-450142, filed on 26 May 1995,  
ABANDONED  
DT Utility  
FS APPLICATION  
LREP Roylance, Abrams, Berdo & Goodman, L.L.P., Suite 600, 1300 19th Street,  
N.W., Washington, DC, 20036  
CLMN Number of Claims: 28  
ECL Exemplary Claim: 1  
DRWN 19 Drawing Page(s)  
LN.CNT 1766

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Stable polynucleotide delivery vehicles (SPDVs) are described which  
incorporate a polynucleotide/cationic lipid complex as structural  
components of the SPDV. The subject SPDVs may optionally incorporate  
synthetic biodegradable amphipathic lipids, and suitable  
targeting agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 24 OF 40 USPATFULL  
AN 2001:196635 USPATFULL  
TI Delivery of nucleic acid materials  
IN Schacht, Etienne H, Rijssseveldstraat 99, B-8140, Staden, Belgium  
Seymour, Leonard C W, The University of Birmingham, Clinical Research  
Block, The Medical School, Edgbaston, Birmingham B15 2TJ, United Kingdom

Ulbrich, Karel, Inst of Macromolecular Chemistry, Academy of Sciences of  
the Czech Republic, Heyrovsky Sq. 2, 16206, Prague 7, Czech Republic

PI US 6312727 B1 20011106  
AI US 1999-306568 19990506 (9)  
RLI Continuation of Ser. No. WO 1997-GB2965, filed on 6 Nov 1997  
PRAI GB 1996-23051 19961106  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: McKelvey, Terry; Assistant Examiner: Sandals, William  
LREP Pillsbury Winthrop LLP  
CLMN Number of Claims: 52  
ECL Exemplary Claim: 1  
DRWN 13 Drawing Figure(s); 11 Drawing Page(s)  
LN.CNT 2173  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Synthetic polymer-based carrier vehicles for delivery of nucleic acid material to target cells in biological systems are made by self-assembly of the nucleic acid with cationic polymer material so as to condense the nucleic acid and form a polyelectrolyte complex and reacting the complex with hydrophilic polymer material which bonds to the complex forming a hydrophilic coating that stabilizes the complex and provides an outer protective steric shield. The carrier vehicles are useful for gene therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 25 OF 40 USPATFULL  
AN 2001:182086 USPATFULL  
TI Novel methods of ultrasound treatment using gas or gaseous precursor-filled compositions  
IN Unger, Evan C., Tucson, AZ, United States  
PA ImaRx Pharmaceutical Corp. (U.S. corporation)  
PI US 2001031243 A1 20011018  
AI US 2001-813484 A1 20010321 (9)  
RLI Division of Ser. No. US 1997-929847, filed on 15 Sep 1997, PENDING  
DT Utility  
FS APPLICATION  
LREP Woodcock Washburn Kurtz, Mackiewicz & Norris LLP, 46th Floor, One Liberty Place, Philadelphia, PA, 19103  
CLMN Number of Claims: 34  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 6360

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes, among other things, the surprising discovery that gaseous precursor filled compositions are profoundly more effective as acoustically active contrast agents when they are thermally preactivated to temperatures at or above the boiling point of the instilled gaseous precursor prior to their in vivo administration to a patient. Further optimization of contrast enhancement is achieved by administering the gaseous precursor filled compositions to a patient as an infusion. Enhanced effectiveness is also achieved for ultrasound mediated targeting and drug delivery.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 26 OF 40 USPATFULL  
AN 2001:109889 USPATFULL  
TI CATIONIC POLYMERS AND LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS  
IN SULLIVAN, SEAN M., DANVILLE, CA, United States  
MENG, XIAO-YING, ALAMEDA, CA, United States  
PI US 2001007771 A1 20010712  
AI US 1997-865375 A1 19970529 (8)  
PRAI US 1996-18377P 19960529 (60)

DT Utility  
FS APPLICATION  
LREP DEAN H. NAKAMURA, ESQUIRE, ROYLANCE, ABRAMS, BERDO AND GOODMAN, LLP,  
1300 19TH STREET, N.W., SUITE 600, WASHINGTON, DC, 20036  
CLMN Number of Claims: 15  
ECL Exemplary Claim: 1  
DRWN 5 Drawing Page(s)  
LN.CNT 1265

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel cationic polymers and cationic lipids, and methods of making and using the same, are provided. The cationic polymers and cationic lipids are useful for the delivery of nucleic acid polymers and oligomers to cells in vitro and in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 27 OF 40 USPATFULL  
AN 2001:102621 USPATFULL  
TI Antisense modulation of Her-4 expression  
IN Bennett, C. Frank, Carlsbad, CA, United States  
Cowser, Lex M., Carlsbad, CA, United States  
PA Isis Pharmaceuticals, Inc., Carlsbad, CA, United States (U.S.  
corporation)  
PI US 6255111 B1 20010703  
AI US 2000-632580 20000731 (9)  
DT Utility  
FS GRANTED  
EXNAM Primary Examiner: McGarry, Sean  
LREP Licata & Tyrrell P.C.  
CLMN Number of Claims: 13  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2555

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Antisense compounds, compositions and methods are provided for modulating the expression of Her-4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Her-4. Methods of using these compounds for modulation of Her-4 expression and for treatment of diseases associated with expression of Her-4 are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 28 OF 40 USPATFULL  
AN 2001:36655 USPATFULL  
TI Antisense inhibition of SHP-2 expression  
IN Bennett, C. Frank, Carlsbad, CA, United States  
Cowser, Lex M., Carlsbad, CA, United States  
PA Isis Pharmaceuticals Inc., Carlsbad, CA, United States (U.S.  
corporation)  
PI US 6200807 B1 20010313  
AI US 1999-358683 19990721 (9)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Elliott, George C.; Assistant Examiner: Zara, Jane  
LREP Law Offices of Jane Massey Licata  
CLMN Number of Claims: 20  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2592

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Antisense compounds, compositions and methods are provided for modulating the expression of SHP-2. The

**compositions comprise antisense compounds,  
particularly antisense oligonucleotides, targeted to  
nucleic acids encoding SHP-2. Methods of using these compounds  
for modulation of SHP-2 expression and for treatment of diseases  
associated with expression of SHP-2 are provided.**

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 29 OF 40 USPATFULL  
AN 2000:127960 USPATFULL  
TI Optoacoustic contrast agents and methods for their use  
IN Unger, Evan C., Tucson, AZ, United States  
Wu, Yunqiu, Tucson, AZ, United States  
PA Imarx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)  
PI US 6123923 20000926  
AI US 1997-993165 19971218 (8)  
PRAI US 1997-46379P 19970513 (60)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Dees, Jose' G.; Assistant Examiner: Sharareh, Shahnam  
LREP Woodcock Washburn Kurtz Mackiewcz & Norris LLP  
CLMN Number of Claims: 54  
ECL Exemplary Claim: 1  
DRWN 11 Drawing Figure(s); 11 Drawing Page(s)  
LN.CNT 6923  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The present invention generally relates to optoacoustic contrast agents  
and methods of diagnostic and therapeutic imaging using optoacoustic  
contrast agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 30 OF 40 USPATFULL  
AN 2000:124825 USPATFULL  
TI Antisense modulation of SHP-1 expression  
IN Bennett, C. Frank, Carlsbad, CA, United States  
Cowser, Lex M., Carlsbad, CA, United States  
PA Isis Pharmaceuticals Inc., Carlsbad, CA, United States (U.S.  
corporation)  
PI US 6121047 20000919  
AI US 1999-358685 19990721 (9)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Elliott, George C.; Assistant Examiner: Schmidt,  
Melissa  
LREP Law Offices of Jane Massey Licata  
CLMN Number of Claims: 20  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 3015  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Antisense compounds, compositions and methods are  
provided for modulating the expression of SHP-1. The  
compositions comprise antisense compounds,  
particularly antisense oligonucleotides, targeted to  
nucleic acids encoding SHP-1. Methods of using these compounds  
for modulation of SHP-1 expression and for treatment of diseases  
associated with expression of SHP-1 are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 31 OF 40 USPATFULL  
AN 2000:97989 USPATFULL  
TI Method to enhance treatment of cystic tumors

IN Fick, James R., Martinez, GA, United States  
PA Medical College of Georgia Research Institute, Inc., Augusta, GA, United States (U.S. corporation)  
PI US 6096303 20000801  
AI US 1997-904097 19970731 (8)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Schwartzman, Robert A.  
LREP Arnall Golden & Gregory, LLP  
CLMN Number of Claims: 22  
ECL Exemplary Claim: 1  
DRWN 4 Drawing Figure(s); 2 Drawing Page(s)  
LN.CNT 1429

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB It has been discovered that **cells** such as genetically engineered fibroblasts and keratinocytes can be cultured in the cyst fluid of encapsulated tumors. This provides a means for proliferating genetically engineered producer **cells** within these types of tumors, increasing the number of **cells** producing viral particles, which then transduce the surrounding tumor **cells** with the genetic material, in the preferred embodiment, a lethal gene. A number of different tumor types form "cysts", which contain fluid produced by the tumor **cells**, including brain tumor **cells** such as gliomas, and many types of breast, and lung tumors. These cyst fluids have been shown to contain elevated levels of certain growth factors, for example, fibroblast growth factor (FGF) and epidermal growth factor (EGF). The types of genetically engineered **cells** to be used can be selected in part according to the levels of growth factors in the cyst fluid which most promote growth of the **cells**, for example, cystic tumors with high levels of FGF would be injected with genetically engineered fibroblasts; cystic tumors with high levels of EGF would be injected with genetically engineered keratinocytes; and cystic tumors with high levels of vascular endothelial growth factor (VEGF) would be injected with genetically engineered endothelial **cells**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 32 OF 40 USPATFULL  
AN 2000:31250 USPATFULL  
TI Antisense inhibition of integrin beta 3 expression  
IN Bennett, C. Frank, Carlsbad, CA, United States  
Monia, Brett P., La Costa, CA, United States  
Cowser, Lex M., Carlsbad, CA, United States  
PA Isis Pharmaceuticals Inc., Carlsbad, CA, United States (U.S. corporation)  
PI US 6037176 20000314  
AI US 1999-344520 19990625 (9)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: LeGuyader, John L.  
LREP Law Offices of Jane Massey Licata  
CLMN Number of Claims: 10  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 2912

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB **Antisense** compounds, **compositions** and methods are provided for modulating the expression of integrin beta 3. The **compositions** comprise **antisense** compounds, particularly **antisense oligonucleotides**, targeted to nucleic acids encoding integrin beta 3. Methods of using these compounds for modulation of integrin beta 3 expression and for treatment of diseases associated with expression of integrin beta 3 are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 33 OF 40 USPATFULL  
AN 2000:21560 USPATFULL  
TI Prodrugs comprising fluorinated **amphiphiles**  
IN Unger, Evan C., Tucson, AZ, United States  
PA Imarx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)  
PI US 6028066 20000222  
AI US 1997-887215 19970702 (8)  
RLI Continuation-in-part of Ser. No. US 1997-851780, filed on 6 May 1997  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Dees, Jose' G.; Assistant Examiner: Badio, Barbara  
LREP Woodcock Washburn Kurtz Mackiewicz & Norris LLP  
CLMN Number of Claims: 8  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 6329

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes, inter alia, novel prodrugs comprising fluorinated **amphiphiles**, **compositions** comprising the novel prodrugs, and methods of use of the prodrugs and **compositions**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 34 OF 40 USPATFULL  
AN 1999:102490 USPATFULL  
TI Tumor delivery vehicles  
IN Fick, James R., Martinez, GA, United States  
PA FBP Corporation, San Francisco, CA, United States (U.S. corporation)  
PI US 5945100 19990831  
AI US 1996-690535 19960731 (8)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Campell, Bruce R.; Assistant Examiner: Nguyen, Dave Trong  
LREP Arnall Golden & Gregory, LLP  
CLMN Number of Claims: 18  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 970

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The major problem with current direct delivery techniques of therapeutic reagents into solid tumors, especially of **cells** or large volumes of recombinant DNA reagents or drugs, has been resistance of the tissues to the influx of the fluid and/or **cells**, resulting in low quantities of the fluid and/or **cells** penetrating into and remaining in the tumor tissue to be treated. Increased penetration and/or reduced backflow and diversion through the point of entry, so that more material is introduced into and remains in the tumor, is obtained through the use of a viscous vehicle, most preferably having a similar density to tissue, for the material to be delivered. Preferred materials include solutions or suspensions of a polymeric material which gel or solidify at the time of or shortly after injection or implantation. In the preferred embodiment, the solution is injected via a catheter into regions of the tumor to be treated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 35 OF 40 USPATFULL  
AN 1998:119169 USPATFULL  
TI Selective prevention of organ injury is sepsis and shock using selective

IN release of nitric oxide vulnerable organs  
Saavedra, Joseph E., Thurmont, MD, United States  
Keefer, Larry K., Bethesda, MD, United States  
PA The United States Of America, as represented by the Department Of Health  
And Human Services, Washington, DC, United States (U.S. corporation)  
PI US 5814656 19980929  
AI US 9428968 19971002 (8)  
RLI Division of Ser. No. 509558, filed on 31 Jul 1995, now patented, Pat.  
No. 5714511  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Henley, III, Raymond  
LREP Leydig, Voit & Mayer, Ltd.  
CLMN Number of Claims: 9  
ECL Exemplary Claim: 1  
DRWN 8 Drawing Figure(s); 4 Drawing Page(s)  
LN.CNT 1003  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB A method for the treatment of mammalian tissue injured or at risk of  
injury during sepsis or shock including the administration to a mammal a  
diazenuimidolate which releases a therapeutically effective amount of  
nitric oxide sufficient to protect the tissue from sepsis- or  
shock-induced injury.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 36 OF 40 USPATFULL  
AN 1998:12052 USPATFULL  
TI Selective prevention of organ injury in sepsis and shock using selection  
release of nitric oxide in vulnerable organs  
IN Saavedra, Joseph E., Thurmont, MD, United States  
Keefer, Larry K., Bethesda, MD, United States  
Billiar, Timothy R., Pittsburgh, PA, United States  
PA The United States of America as represented by the Secretary of the  
Department of Health and Human Services, Washington, DC, United States  
(U.S. government)  
The University of Pittsburgh, Pittsburgh, PA, United States (U.S.  
corporation)  
PI US 5714511 19980203  
AI US 1995-509558 19950731 (8)  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Henley, III, Raymond  
LREP Leydig, Voit & Mayer, Ltd.  
CLMN Number of Claims: 27  
ECL Exemplary Claim: 1  
DRWN 8 Drawing Figure(s); 4 Drawing Page(s)  
LN.CNT 1646  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB A method for the treatment of mammalian tissue injured or at risk of  
injury during sepsis or shock including the administration to a mammal a  
diazenuimidolate which releases a therapeutically effective amount of  
nitric oxide sufficient to protect the tissue from sepsis- or  
shock-induced injury.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> dis hist

(FILE 'HOME' ENTERED AT 10:28:06 ON 01 APR 2003)

FILE 'APOLLIT, BABS, CAPLUS, CBNB, CEN, CIN, EMA, IFIPAT, JICST-EPLUS,  
PASCAL, PLASNEWS, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL,  
USPAT2, WPINDEX, WTEXTILES' ENTERED AT 10:28:22 ON 01 APR 2003

L1 4583415 S COMPOSITION  
L2 26461 S L1 AND (POLYSACCHARIDE AND ?AMINE)  
L3 3258 S L1 AND (POLYSACCHARIDE AND POLYAMINE)  
L4 2816 S L3 AND (ALKYL OR HYDROPHOB? OR AMPHIPHIL?)  
L5 1815 S L4 AND (NUCLEIC OR PROTEIN)  
L6 1616 S L5 AND (DEXTRAN OR ARABINOGALACTAN OR PULLULAN OR CELLULOSE)  
L7 559 S L6 AND (SPERMINE OR SPERMIDINE OR POLYETHYLENEIMINE)  
L8 405 S L7 AND (BIOLOGICAL OR MEMBRANE)  
L9 255 S L8 AND BIODEGRA?  
L10 245 S L9 AND (CELL OR TRANSFECT?)  
L11 220 S L10 AND PEPTIDE  
L12 204 S L11 AND (POLYNUCLEIC OR OLIGONUCLEOTIDE OR ANTISENSE)  
L13 203 S L12 AND (FATTY OR OLEIC OR GLYCOL)  
L14 40 S L13 AND (TOXIC OR IMMUNOG?)

INDEX 'APOLLIT, BABS, CAPLUS, CBNB, CEN, CIN, EMA, IFIPAT, JICST-EPLUS,  
PASCAL, PLASNEWS, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL,  
USPAT2, WPIDS, WPINDEX, WTEXTILES' ENTERED AT 10:43:00 ON 01 APR 2003

SEA L14

-----

40 FILE USPATFULL

L15 QUE L14

-----

FILE 'USPATFULL' ENTERED AT 10:45:45 ON 01 APR 2003

L16 40 S L14